NYSE · BDX · Medical Instruments & Supplies
Becton, Dickinson and Company (BDX) stock analysis
- BDX gained 6.2% over the past month versus 0.0% for the S&P 500, ranking 145th of 497 S&P 500 stocks.
- Over 12 months it returned +31.0%, 15.2 points ahead of the S&P 500, and trades 0.0% below its 52-week high.
- In the last 30 days 3 analysts raised earnings estimates and 0 cut; forward EPS moved +0.1% (−0.7% over 90 days).
- It sits in the Supplies, sterilization & packaging segment of the Medtech, Diagnostics & Care, where the 1-month median return is +6.0%.
- The daily chart reads Intermediate uptrend · Trend advance (since Oct 14, 2026).
One-year price with 50- and 200-day averages
Performance vs the market
Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.
Chart structure
Read by our daily-bar structure engine from swing highs, swing lows and moving averages.
Holding since Oct 14, 2026
- Close above EMA20 above EMA50
- EMA50 rose over the last ten sessions
- Some swings conflict with the averages
63 occurrences in 10 years. The median move over the next 20 sessions was −0.5%, positive 44% of the time, against +0.6% for any day in the same period.
Analyst earnings revisions
Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.
12 analysts cover the stock
Where it sits in the supply chain
Medtech, Diagnostics & Care · Devices, supplies & tests
Supplies, infection control and packaging serve different medical settings.
Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps
Risk profile
Track this stock every day
Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.